Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy.

Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.

Br J Cancer. 2013 May 28;108(10):1978-84. doi: 10.1038/bjc.2013.232. Epub 2013 May 7.

2.

Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.

Kim SH, Shin SJ, Lee KY, Kim H, Kim TI, Kang DR, Hur H, Min BS, Kim NK, Chung HC, Roh JK, Ahn JB.

Ann Surg Oncol. 2013 Oct;20(11):3407-13. doi: 10.1245/s10434-013-3169-1. Epub 2013 Aug 14.

PMID:
23943026
3.

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.

Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.

Int J Cancer. 2013 May 1;132(9):2209-16. doi: 10.1002/ijc.27888. Epub 2012 Oct 29.

4.

KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.

Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.

Ann Surg Oncol. 2015 Jan;22(1):187-94. doi: 10.1245/s10434-014-3826-z. Epub 2014 Jun 3.

PMID:
24889488
5.

Prognostic implication of mucinous histology in resected colorectal cancer liver metastases.

Lupinacci RM, Mello ES, Coelho FF, Kruger JA, Perini MV, Pinheiro RS, Fonseca GM, Cecconello I, Herman P.

Surgery. 2014 Jun;155(6):1062-8. doi: 10.1016/j.surg.2014.01.011. Epub 2014 Feb 5.

PMID:
24856126
6.

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.

Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.

Cancer Chemother Pharmacol. 2011 Aug;68(2):317-23. doi: 10.1007/s00280-010-1496-5. Epub 2010 Oct 24.

PMID:
20972872
7.

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.

An MS, Yoo JH, Kim KH, Bae KB, Choi CS, Hwang JW, Kim JH, Kim BM, Kang MS, Oh MK, Hong KH.

World J Surg Oncol. 2015 Feb 19;13:64. doi: 10.1186/s12957-015-0488-7.

8.

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.

Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.

Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67. doi: 10.1007/s00280-009-1206-3. Epub 2009 Dec 24.

PMID:
20033812
9.

Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.

Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.

Clin Cancer Res. 2011 Dec 1;17(23):7470-8. doi: 10.1158/1078-0432.CCR-11-1048. Epub 2011 Oct 13.

10.

[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].

Qiu MZ, Teng KY, Ruan DY, Li YH, Chen XQ, Pan ZZ, He YJ, Wan DS, Xu RH.

Ai Zheng. 2009 Jul;28(7):743-8. Chinese.

PMID:
19624903
11.

Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer.

Maisano R, Azzarello D, Maisano M, Mafodda A, Bottari M, Egitto G, Nardi M.

J Chemother. 2012 Aug;24(4):212-6. doi: 10.1179/1973947812Y.0000000013.

PMID:
23040685
12.

Inverse effect of mucinous component on survival in stage III colorectal cancer.

Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Yamamoto G, Nishimura Y, Yamaguchi K.

J Surg Oncol. 2014 Dec;110(7):851-7. doi: 10.1002/jso.23742. Epub 2014 Aug 11.

PMID:
25111953
13.

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN.

Ann Surg. 2012 Oct;256(4):642-50. doi: 10.1097/SLA.0b013e31826b4dcc.

14.

How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?

Suenaga M, Matsusaka S, Watanabe T, Kuboki Y, Shinozaki E, Chin K, Mizunuma N, Ueno M, Yamaguchi T, Hatake K.

Asia Pac J Clin Oncol. 2011 Jun;7(2):129-35. doi: 10.1111/j.1743-7563.2011.01385.x.

PMID:
21585692
15.

Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.

Uncu D, Aksoy S, Çetin B, Yetişyiğit T, Özdemir N, Berk V, Dane F, Inal A, Harputluoğlu H, Budakoğlu B, Koca D, Sevinç A, Cihan S, Durnalı AG, Özkan M, Öztürk MA, Işıkdoğan A, Büyükberber S, Benekli M, Köş T, Alkış N, Karaca H, Turhal NS, Zengin N; Anatolian Society of Medical Oncology.

Oncology. 2013;84(4):240-5. doi: 10.1159/000336902. Epub 2013 Feb 7.

PMID:
23392240
16.

Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.

Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG.

Oncology. 2009;76(5):363-8. doi: 10.1159/000210025. Epub 2009 Mar 25.

PMID:
19321964
17.

Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?

Madbouly KM, Hussein AM, Zeid A.

Dis Colon Rectum. 2013 May;56(5):577-85. doi: 10.1097/DCR.0b013e318286f8fc. Erratum in: Dis Colon Rectum. 2015 Mar;58(3):369.

PMID:
23575396
18.

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.

J Clin Oncol. 2012 Oct 10;30(29):3596-603. doi: 10.1200/JCO.2012.42.6031. Epub 2012 Sep 10.

PMID:
22965965
19.

[Clinical features of colorectal mucinous adenocarcinoma].

Song W, He YL, Cai SR, Zhang CH, Chen CQ, Peng JJ, Zhan WH.

Zhonghua Wei Chang Wai Ke Za Zhi. 2009 Sep;12(5):487-90. Chinese.

PMID:
19742341
20.

Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.

Cercek A, Siegel CL, Capanu M, Reidy-Lagunes D, Saltz LB.

Clin Colorectal Cancer. 2013 Sep;12(3):163-7. doi: 10.1016/j.clcc.2013.04.007. Epub 2013 Jul 17.

PMID:
23871161

Supplemental Content

Support Center